Answers are grounded in this paper and cite their sources.
In this Brief Report we provide updated results (October 11, 2023 through February 29, 2024) from our previously conducted test-negative case-control study in Kaiser Permanente Southern California to evaluate sub-lineage-specific effectiveness of the BNT162b2 XBB1.5-adapted vaccine. Results suggest that XBB1.5-adapted vaccines may have reduced effectiveness against JN.1 versus XBB sub-lineages.
No takes yet. Share an insight, caveat, or question.
Tartof et al. (2024) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: